Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

95MO Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)

Autor: Gupta, T., Garcia, C., Biederman, S., Kalashnikova, E., Rodriguez, A.A., Liu, M.C., Keenan, J., Medford, A.J., Isakoff, S., Bardia, A., Telli, M.L., Ho, A.Y.

Publikováno v: In ESMO Open May 2023 8(1) Supplement 4

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Autor: Shi Z, Wulfkuhle J, Nowicka M, Gallagher R, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho J, Gil-Gil M, Bermejo B, Pratt D, Ciruelos E, Villagrasa P, Wongchenko M, Petricoin E, Oliveira M, Isakoff S

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

Purpose: Despite extensive genomic and transcriptomic profiling, it remains unknown how signaling pathways are differentially activated and how tumors are differentially sensitized to certain perturbations. Here, we aim to characterize AKT signaling

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::c4be4dca562117d34c81402c85b5c9ae
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16447

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

Autor: Dent R, Oliveira M, Isakoff S, Im S, Espie M, Blau S, Tan A, Saura C, Wongchenko M, Xu N, Bradley D, Reilly S, Mani A, Kim S, LOTUS Investigators, LOTUS investigators

Publikováno v: BREAST CANCER RESEARCH AND TREATMENT
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname

Purpose In LOTUS (NCT02162719), adding the oral AKT inhibitor ipatasertib to first-line paclitaxel for locally advanced/metastatic triple-negative breast cancer (aTNBC) improved progression-free survival (PFS; primary endpoint), with an enhanced effe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::b5939b77c59216ad62d19e8bf3f795c4
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16260

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.